skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Relugolix (Code C114498)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Relugolix

Definition: An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Label: Relugolix

NCI Thesaurus Code: C114498 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3252109  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
TAK 385
Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-

External Source Codes: 
CAS Registry Number 737789-87-6 (see NLM ChemIDplus info)
FDA UNII Code P76B05O5V6
PDQ Closed Trial Search ID 759257
PDQ Open Trial Search ID 759257 (check for NCI PDQ open clinical trial info)
UMLS CUI C3252109

Other Properties:
     Name Value (qualifiers indented underneath)
code C114498
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom